Evidence map›Paper›PMID 35575919›Full record

ArticleAdvances in experimental medicine and biology2022

HDL and Endothelial Function.

Yufei Wu, Yangkai Xu, Jie Chen, Mingming Zhao, Kerry-Anne Rye

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
14.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. ANGPTL3 is a novel HDL component that regulates HDL function.Journal of translational medicine · 2024
    Article
  8. Article
  9. HDL as a Treatment Target: Should We Abandon This Idea?Current atherosclerosis reports · 2023
    Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Yufei WuThe Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, Key Laboratory of Molecular Cardiovascular Science of Ministry of Education, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Health Science Center, Peking University, Beijing, China. Cardio_wu@163.com.
Yangkai XuThe Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, Key Laboratory of Molecular Cardiovascular Science of Ministry of Education, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Health Science Center, Peking University, Beijing, China.
Jie ChenThe Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, Key Laboratory of Molecular Cardiovascular Science of Ministry of Education, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Health Science Center, Peking University, Beijing, China.
Mingming ZhaoThe Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, Key Laboratory of Molecular Cardiovascular Science of Ministry of Education, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Health Science Center, Peking University, Beijing, China.
Kerry-Anne RyeLipid Research Group, School of Medical Sciences, Level 4E, Wallace Wurth Building, University of New South Wales Sydney, Sydney, NSW, Australia.
Peking University · CNUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plasmid high-density lipoprotein (HDL) is a critical biomarker in predicting cardiovascular diseases. Endothelial cells are physically located in the intima of blood vessels, which directly contact with circulating substances. Numerous previous studies have demonstrated that HDL exert protective effects on maintaining endothelial integrity and enhance anti-inflammatory functions, etc. In this chapter, we introduced how HDL benefit endothelial functions. We summarized the function of HDL on endothelial cell, such as endothelial permeability, proliferation, migration, apoptosis, etc. In addition, we discussed the effects of HDL on classical endothelial functions, such as coagulation and vasodilation. Although HDL have huge effects on endothelial functions, lots of cardiovascular diseases such as atherosclerosis could not be fully prevented and treated. Thus, a further understanding of the relationship between HDL and endothelial cell is needed, which would create a potential therapeutic approach to cardiovascular diseases.

Indexed as

AtherosclerosisCardiovascular DiseasesEndothelial CellsHumansLipoproteins, HDLVasodilationLipoproteins, HDLEndothelial barrier integrityEndothelial cellsEndothelial functionHDL

Identifiers

PMID35575919
OpenAlexW4285194775

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.